FBLG

FibroBiologics, Inc.

Price Chart

Latest Quote

$0.83

-0.00 (-0.58%)

Current Price

Previous Close	$0.84
Open	$0.82
Day High	$0.84
Day Low	$0.81
Volume	154,064

Fetched: 2026-07-18T09:11:18

Stock Information

Shares Outstanding	5.21M
Total Debt	$2.48M
Cash Equivalents	$1.48M
Net Income	$-18.68M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$4.35M
EPS (TTM)	$-6.94
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$5.34M
Income	$-18.68M
Book/sh	$0.74
Cash/sh	$0.28
Employees	15

Financial Ratios

Quick Ratio	0.81
Current Ratio	1.59
Debt/Eq	95.31

Returns & Margins

ROA	-123.72%
ROE	-754.75%

Ownership

Insider Ownership	10.81%
Institutional Ownership	10.72%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-0.19
P/B	1.13

Analyst Data

Recommendation	none
Target Price	$13.50

Technical Indicators

SMA20	$0.84
SMA50	$0.96
SMA200	$4.53
RSI	50.91
ATR	0.0631

Shares Float	4.57M
Short Float	2.78%
Short Ratio	0.66
Volatility	1.17
Rel Volume	0.97

Performance History

Week	-8.94%
Month	+3.09%
Quarter	-45.07%
6 Months	-87.72%
YTD	-82.60%
Year	-94.18%
10 Years	-99.86%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$0.83	154,300
2026-07-16	$0.84	40,300
2026-07-15	$0.84	26,700
2026-07-14	$0.85	39,400
2026-07-13	$0.86	66,500
2026-07-10	$0.92	76,400
2026-07-09	$0.86	71,300
2026-07-08	$0.82	52,300
2026-07-07	$0.84	46,700
2026-07-06	$0.87	59,200
2026-07-02	$0.88	58,900
2026-07-01	$0.91	106,600
2026-06-30	$0.95	268,900
2026-06-29	$0.80	231,000
2026-06-26	$0.83	1,098,800
2026-06-25	$0.73	80,100
2026-06-24	$0.77	151,300
2026-06-23	$0.75	247,100
2026-06-22	$0.81	158,100
2026-06-18	$0.77	160,400

About FibroBiologics, Inc.

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

📰 Latest News

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial

Benzinga • 2026-06-03T10:46:42Z

Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?

Insider Monkey • 2026-06-02T13:57:45Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$204,000	$20,000	$147,000	$654,000
Total Expenses	$16,649,000	$13,737,000	$8,889,000	$4,467,000
Other Income Expense	$-2,040,000	$2,345,000	$-7,449,000	-
Other Non Operating Income Expenses	$-2,392,000	$-3,377,000	$-213,000	-
Net Non Operating Interest Income Expense	$43,000	$231,000	$-147,000	$-654,000
Interest Expense Non Operating	$204,000	$20,000	$147,000	$654,000
Operating Expense	$16,649,000	$13,737,000	$8,889,000	$4,467,000
General And Administrative Expense	$9,242,000	$9,233,000	$6,521,000	$3,320,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-18,646,000	$-11,161,000	$-16,485,000	$-5,121,000
Net Interest Income	$43,000	$231,000	$-147,000	$-654,000
Interest Income	$247,000	$251,000	$0	-
Normalized Income	$-18,998,000	$-16,883,000	$-9,249,000	$-5,121,000
Net Income From Continuing And Discontinued Operation	$-18,646,000	$-11,161,000	$-16,485,000	$-5,121,000
Total Operating Income As Reported	$-16,649,000	$-13,737,000	$-8,889,000	$-4,467,000
Net Income Common Stockholders	$-18,646,000	$-11,161,000	$-19,058,000	$-5,121,000
Net Income	$-18,646,000	$-11,161,000	$-16,485,000	$-5,121,000
Net Income Including Noncontrolling Interests	$-18,646,000	$-11,161,000	$-16,485,000	$-5,121,000
Net Income Continuous Operations	$-18,646,000	$-11,161,000	$-16,485,000	$-5,121,000
Pretax Income	$-18,646,000	$-11,161,000	$-16,485,000	$-5,121,000
Interest Income Non Operating	$247,000	$251,000	$0	-
Operating Income	$-16,649,000	$-13,737,000	$-8,889,000	$-4,467,000
Per Share
Diluted EPS	$-8.40	$-6.80	$-11.74	$-3.15
Basic EPS	$-8.40	$-6.80	$-11.74	$-3.15
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-17,962,000	$-16,290,000	$-8,665,000	$-4,373,000
Total Unusual Items	$352,000	$5,722,000	$-7,236,000	-
Total Unusual Items Excluding Goodwill	$352,000	$5,722,000	$-7,236,000	-
Reconciled Depreciation	$832,000	$573,000	$437,000	$94,000
EBITDA (Bullshit earnings)	$-17,610,000	$-10,568,000	$-15,901,000	$-4,373,000
EBIT	$-18,442,000	$-11,141,000	$-16,338,000	$-4,467,000
Diluted Average Shares	$2,233,025	$1,643,753	$1,624,603	$1,623,860
Basic Average Shares	$2,233,025	$1,643,753	$1,624,603	$1,623,860
Diluted NI Availto Com Stockholders	$-18,646,000	$-11,161,000	$-19,058,000	$-5,121,000
Gain On Sale Of Security	$352,000	$5,722,000	$-7,236,000	-
Research And Development	$7,407,000	$4,504,000	$2,368,000	$1,147,000
Selling General And Administration	$9,242,000	$9,233,000	$6,521,000	$3,320,000
Other Gand A	$9,242,000	$9,233,000	$6,521,000	$3,320,000
Otherunder Preferred Stock Dividend	-	$0	$2,573,000	$0

Fetched: 2026-07-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$6,156,000	$2,735,000	$1,253,000	$-3,996,000
Total Assets	$9,619,000	$16,445,000	$11,821,000	$4,824,000
Total Non Current Assets	$3,270,000	$2,217,000	$2,606,000	$2,199,000
Other Non Current Assets	$48,000	-	-	-
Current Assets	$6,349,000	$14,228,000	$9,215,000	$2,625,000
Prepaid Assets	$1,455,000	$225,000	$36,000	$29,000
Cash Cash Equivalents And Short Term Investments	$4,894,000	$13,985,000	$9,163,000	$2,266,000
Cash And Cash Equivalents	$4,894,000	$13,985,000	$9,163,000	$2,266,000
Other Current Assets	-	$18,000	$16,000	$30,000
Receivables	-	-	$0	$300,000
Loans Receivable	-	-	$0	$300,000
Debt
Total Debt	$2,410,000	$10,553,000	$1,747,000	$7,524,000
Long Term Debt And Capital Lease Obligation	$1,704,000	$984,000	$1,385,000	$1,747,000
Current Debt And Capital Lease Obligation	$706,000	$9,569,000	$362,000	$5,777,000
Current Debt	-	$9,168,000	-	$5,451,000
Other Current Borrowings	-	$9,168,000	-	$5,451,000
Net Debt	-	-	-	$3,185,000
Liabilities
Total Liabilities Net Minority Interest	$3,463,000	$13,710,000	$10,568,000	$8,820,000
Total Non Current Liabilities Net Minority Interest	$1,704,000	$984,000	$1,385,000	$1,747,000
Current Liabilities	$1,759,000	$12,726,000	$9,183,000	$7,073,000
Other Current Liabilities	$108,000	$460,000	$7,236,000	$538,000
Payables And Accrued Expenses	$945,000	$2,697,000	$1,585,000	$758,000
Payables	$945,000	$2,697,000	$1,585,000	$758,000
Accounts Payable	$945,000	$2,697,000	$1,444,000	$758,000
Other Non Current Liabilities	-	-	$1,000	-
Other Payable	-	-	$141,000	-
Equity
Common Stock Equity	$6,156,000	$2,735,000	$1,253,000	$-3,996,000
Total Equity Gross Minority Interest	$6,156,000	$2,735,000	$1,253,000	$-3,996,000
Stockholders Equity	$6,156,000	$2,735,000	$1,253,000	$-3,996,000
Retained Earnings	$-54,164,000	$-35,518,000	$-24,357,000	$-7,872,000
Other Equity Interest	-	-	-	$1,461,000
Other
Ordinary Shares Number	$3,325,986	$1,754,285	$1,623,860	$1,623,860
Share Issued	$3,325,986	$1,754,285	$1,623,860	$1,623,860
Tangible Book Value	$6,156,000	$2,735,000	$1,253,000	$-3,996,000
Invested Capital	$6,156,000	$11,903,000	$1,253,000	$1,455,000
Working Capital	$4,590,000	$1,502,000	$32,000	$-4,448,000
Capital Lease Obligations	$2,410,000	$1,385,000	$1,747,000	$2,073,000
Total Capitalization	$6,156,000	$2,735,000	$1,253,000	$-3,996,000
Additional Paid In Capital	$60,319,000	$38,253,000	$25,609,000	$2,414,000
Capital Stock	$1,000	$0	$1,000	$1,000
Common Stock	$1,000	$0	$1,000	$1,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$1,704,000	$984,000	$1,385,000	$1,747,000
Current Capital Lease Obligation	$706,000	$401,000	$362,000	$326,000
Net PPE	$3,222,000	$2,217,000	$2,606,000	$2,199,000
Accumulated Depreciation	$-448,000	$-204,000	$-47,000	$0
Gross PPE	$3,670,000	$2,421,000	$2,653,000	$2,199,000
Other Properties	$3,578,000	$2,374,000	$2,625,000	$2,199,000
Machinery Furniture Equipment	$92,000	$47,000	$28,000	$0
Dueto Related Parties Current	-	$0	$141,000	$0

Fetched: 2026-07-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-16,656,000	$-12,085,000	$-6,896,000	$-4,066,000
Operating Activities
Operating Cash Flow	$-16,394,000	$-11,901,000	$-6,401,000	$-4,066,000
Cash Flow From Continuing Operating Activities	$-16,394,000	$-11,901,000	$-6,401,000	$-4,066,000
Operating Gains Losses	$273,000	$-5,722,000	$7,308,000	-
Investing Activities
Capital Expenditure	$-262,000	$-184,000	$-495,000	-
Investing Cash Flow	$-262,000	$-184,000	$-495,000	$0
Cash Flow From Continuing Investing Activities	$-262,000	$-184,000	$-495,000	$0
Financing Activities
Issuance Of Capital Stock	$6,590,000	$7,507,000	$16,138,000	$2,150,000
Financing Cash Flow	$7,565,000	$16,907,000	$13,793,000	$5,925,000
Cash Flow From Continuing Financing Activities	$7,565,000	$16,907,000	$13,793,000	$5,925,000
Net Common Stock Issuance	$6,590,000	$7,507,000	$0	-
Common Stock Issuance	$6,590,000	$7,507,000	$0	-
Net Preferred Stock Issuance	-	$0	$16,138,000	$2,150,000
Preferred Stock Issuance	-	$0	$16,138,000	$2,150,000
Net Other Financing Charges	-	-	$-2,645,000	-
Other
Repayment Of Debt	$-3,400,000	$0	$0	$-525,000
Issuance Of Debt	$4,375,000	$9,400,000	$300,000	$4,300,000
Interest Paid Supplemental Data	$204,000	$20,000	$2,000	$0
Income Tax Paid Supplemental Data	$0	$0	$0	$0
End Cash Position	$4,894,000	$13,985,000	$9,163,000	$2,266,000
Beginning Cash Position	$13,985,000	$9,163,000	$2,266,000	$407,000
Changes In Cash	$-9,091,000	$4,822,000	$6,897,000	$1,859,000
Net Issuance Payments Of Debt	$975,000	$9,400,000	$300,000	$3,775,000
Net Short Term Debt Issuance	$975,000	$9,400,000	$300,000	$3,775,000
Short Term Debt Payments	$-3,400,000	$0	$0	$-525,000
Short Term Debt Issuance	$4,375,000	$9,400,000	$300,000	$4,300,000
Net PPE Purchase And Sale	$-262,000	$-184,000	$-495,000	$0
Purchase Of PPE	$-262,000	$-184,000	$-495,000	$0
Change In Working Capital	$-3,312,000	$559,000	$493,000	$307,000
Change In Other Current Liabilities	$-550,000	$-362,000	$-326,000	$-220,000
Change In Other Current Assets	$-30,000	$-2,000	$14,000	$-6,000
Change In Payables And Accrued Expense	$-1,502,000	$1,112,000	$812,000	$525,000
Change In Payable	$-1,502,000	$1,112,000	$812,000	$525,000
Change In Account Payable	$-1,502,000	$1,253,000	$671,000	$525,000
Change In Prepaid Assets	$-1,230,000	$-189,000	$-7,000	$8,000
Stock Based Compensation	$2,686,000	$2,219,000	$1,765,000	$265,000
Unrealized Gain Loss On Investment Securities	$1,773,000	$-232,000	$0	-
Depreciation Amortization Depletion	$832,000	$573,000	$437,000	$94,000
Depreciation And Amortization	$832,000	$573,000	$437,000	$94,000
Depreciation	$832,000	$573,000	$437,000	$94,000
Gain Loss On Investment Securities	$-352,000	$-5,722,000	$7,308,000	-
Net Income From Continuing Operations	$-18,646,000	$-11,161,000	$-16,485,000	$-5,121,000
Other Non Cash Items	-	$1,863,000	$81,000	$389,000

Fetched: 2026-07-15